Bioventus Inc. (BVS) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 4 Buy, 2 Hold.
The consensus price target is $13.00, representing an upside of 31.2% from the current price $9.91.
Analysts estimate Earnings Per Share (EPS) of $0.40 and revenue of $0.57B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.75 vs est $0.40 (missed -286.5%). 2025: actual $0.34 vs est $0.66 (missed -48.6%). Analyst accuracy: 0%.
BVS Stock — 12-Month Price Forecast
$13.00
▲ +31.18% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for Bioventus Inc., the price target is $13.00.
The average price target represents a +31.18% change from the last price of $9.91.
BVS Analyst Ratings
Buy
Based on 6 analysts giving stock ratings to Bioventus Inc. in the past 3 months
EPS Estimates — BVS
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.75
vs Est $0.40
▼ 153.6% off
2025
Actual $0.34
vs Est $0.66
▼ 94.5% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — BVS
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.573B
vs Est $0.565B
▲ 1.5% off
2025
Actual $0.568B
vs Est $0.566B
▲ 0.4% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
